Journal
ALZHEIMERS & DEMENTIA
Volume 15, Issue 2, Pages 194-204Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2018.08.014
Keywords
Alzheimer's disease; beta-amyloid; Prediction; Diagnostic accuracy; Cerebrospinal fluid; A beta(42); Risk estimation; Position emission tomography; Plasma A beta(42)/A beta(40)
Categories
Funding
- European Research Council
- Swedish Research Council
- Marianne and Marcus Wallenberg foundation
- Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University
- Swedish Brain Foundation
- Skane University Hospital Foundation
- Swedish Alzheimer Association
- Swedish federal government under the ALF agreement
- GE Healthcare
- DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Araclon Biotech
- Biogen Idec Inc.
- Eisai Inc.
- Elan Pharmaceuticals, Inc.
- Eli Lilly and Company
- EuroImmun
- F. Hoffmann-La Roche Ltd
- Fujirebio
- Johnson & Johnson Pharmaceutical Research & Development LLC.
- Medpace, Inc.
- Merck Co., Inc.
- Meso Scale Diagnostics, LLC.
- NeuroRx Research
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Piramal Imaging
- Synarc Inc.
- Takeda Pharmaceutical Company
- Canadian Institutes of Health Research
- Swedish federal government under F. Hoffmann-Roche Ltd.
- BioClinica, Inc.
- Bristol-Myers Squibb Company
- Genentech, Inc.
- IXICO Ltd.
- Janssen Alzheimer Immunotherapy Research & Development, LLC.
- Neurotrack Technologies
- Servier
- Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
Ask authors/readers for more resources
Introduction: The aim was to create readily available algorithms that estimate the individual risk of beta-amyloid (A beta) positivity. Methods: The algorithms were tested in BioFINDER (n = 391, subjective cognitive decline or mild cognitive impairment) and validated in Alzheimer's Disease Neuroimaging Initiative (n = 661, subjective cognitive decline or mild cognitive impairment). The examined predictors of A beta status were demographics; cognitive tests; white matter lesions; apolipoprotein E (APOE); and plasma A beta(42)/A beta(40), tau, and neurofilament light. Results: A beta status was accurately estimated in BioFINDER using age, 10-word delayed recall or Mini-Mental State Examination, and APOE (area under the receiver operating characteristics curve 5 0.81 [0.77-0.85] to 0.83 [0.79-0.87]). When validated, the models performed almost identical in Alzheimer's Disease Neuroimaging Initiative (area under the receiver operating characteristics curve 5 0.80-0.82) and within different age, subjective cognitive decline, and mild cognitive impairment populations. Plasma A beta(42)/A beta(40) improved the models slightly. Discussion: The algorithms are implemented on http://amyloidrisk.com where the individual probability of being A beta positive can be calculated. This is useful in the workup of prodromal Alzheimer's disease and can reduce the number needed to screen in Alzheimer's disease trials. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available